FDA drug repurposing uncovers modulators of dopamine D2 receptor localization via disruption of the NCS-1 interaction
Daniel Muñoz-Reyes, Lorena Aguado, Sandra Arroyo‐Urea, Carlos Requena-Triguero, Sara Pérez-Suárez, Sonia Sánchez-Yepes, Josep Argerich, Celia Miró-Rodríguez, Eugenia Ulzurrun, Eulalia Rodríguez‐Martín, Javier García‐Nafría, Nuria Eugenia Campillo, Alicia Mansilla, María José Sánchez-Barrena
The paper identifies FDA-approved drugs that disrupt the NCS-1/D2R interaction, modulating D2R localization without affecting its signaling.
Journal of Medicinal Chemistry · Nov 10, 2025Peer-reviewedBiochemistry